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Abstract
Background Transarterial chemoembolization (TACE) is an important therapy for hepatocellular carcinoma (HCC) in cir-
rhosis. In particular in advanced cirrhosis, post-TACE hepatic failure liver (PTHF) failure may develop. Currently, there is no 
standardization for the periinterventional risk assessment. The liver maximum capacity (LiMAx) test assesses the functional 
liver capacity, but has not been investigated in this setting.
Aims The aim of this study was to prospectively evaluate periinterventional LiMAx and CT volumetry measurements in 
patients with cirrhosis and HCC undergoing repetitive TACE.
Methods From 06/2016 to 11/2017, eleven patients with HCC and cirrhosis undergoing TACE were included. LiMAx 
measurements (n = 42) were conducted before and after each TACE. Laboratory parameters were correlated with the vol-
ume–function data.
Results The median LiMAx levels before (276 ± 166 µg/kg/h) were slightly reduced after TACE (251 ± 122 µg/kg/h; 
p = 0.08). This corresponded to a median drop of 7.1%. Notably, there was a significant correlation between LiMAx levels 
before TACE and bilirubin (but not albumin nor albumin–bilirubin [ALBI] score) increase after TACE (p = 0.02, k = 0.56). 
Furthermore, a significantly higher increase in bilirubin in patients with LiMAx ≤ 150 µg/kg/h was observed (p = 0.011). 
LiMAx levels at different time points in single patients were similar (p = 0.2).
Conclusion In our prospective pilot study in patients with HCC and cirrhosis undergoing multiple TACE, robust and reli-
able LiMAx measurements were demonstrated. Lower LiMAx levels before TACE were associated with surrogate markers 
(bilirubin) of liver failure after TACE. Specific subgroups at high risk of PTHF should be investigated. This might facilitate 
the future development of strategies to prevent occurrence of PTHF.




ALT  Alanine aminotransferase
AFP  Alpha-fetoprotein
BCLC  Barcelona Clinic Liver Cancer Classification
CPS  Child–Pugh score
CT  Computed tomography
EV  Embolization volume
FLRV  Functional remnant liver volume
FRLF  Future remnant liver function
HBV  Hepatitis B virus
HCC  Hepatocellular carcinoma
INR  International normalized ratio
LiMAx  Liver maximum capacity
LV  Liver volume
MELD  Model for end-stage liver disease
PBC  Primary biliary cholangitis
PTHF  Post-TACE hepatic failure
TLV  Total liver volume
TuV  Tumor volume (TuV)
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SD  Standard deviation
TACE  Transarterial chemoembolization
TIPS  Transhepatic intrahepatic portosystemic shunt
TKI  Tyrosinkinase inhibitor
Introduction
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and the third most common cancer-dependent 
death cause worldwide [1]. Transarterial chemoemboliza-
tion (TACE) is the gold standard palliative therapy in non-
resectable Barcelona Clinic Liver Cancer Classification 
(BCLC) stage B patients and also used for bridging patients 
to liver transplantation [2]. It is well known that the prog-
nosis depends on tumor burden and liver function capacity. 
TACE is less effective in patients with extrahepatic spread 
or macrovascular invasion, and/or decompensated liver dis-
ease [2]. Post-TACE hepatic failure (PTHF) is severe com-
plication after TACE. Several scoring systems and algo-
rithms for HCC patients have been evaluated in the past [3]. 
Child–Pugh stage B or C and serum bilirubin level > 2 mg/
dl are considered as risk factors for liver failure after TACE 
[4, 5]. Currently, the ALBI-[6] and other scores are applied. 
However, there is still no widely accepted standard risk 
assessment procedure in patients undergoing TACE.
The liver maximum capacity (LiMAx) test was intro-
duced for the evaluation of the liver function capacity. 
LiMAx was initially developed and proved beneficial to 
predict postoperative liver function in patients after hepa-
tectomy [7]. In the further course, it was used to assess the 
severity of liver cirrhosis and the short-term mortality of 
cirrhosis patients and HCC patients undergoing hepatectomy 
[8, 9]. Previous studies found a strong correlation between 
LiMAx levels and histological severity of liver disease [10] 
and different clinical stages of cirrhosis [11].
Moreover, we previously evaluated the ability to predict 
the functional reserve in patients with cirrhosis and transhe-
patic intrahepatic portosystemic shunt (TIPS) implantation 
[8].
The aim of this study was to prospectively assess LiMAx 




The study was reviewed and approved by an institutional 
research review board (Approval 266/16). Each patient 
signed a written informed consent for the study and TACE 
procedure, as well as informed consent to use the clinical 
data for this research project. All patients evaluated for 
TACE in our departments between June 2016 and Novem-
ber 2017 were screened for inclusion. Only patients with 
HCC and cirrhosis were included in the analysis. HCC 
was diagnosed according to EASL criteria [2]. All patients 
were discussed in the local tumor board, and TACE was 
recommended. Since a total bilirubin level > 3.0 mg/dl is 
considered as a contraindication for TACE in our center, 
no such patients were enrolled. Age < 18 years, paraceta-
mol allergy, and the inability to perform all the necessary 
study examinations were exclusion criteria. Before TACE, 
all patients received a clinical examination including labo-
ratory liver function tests and magnetic resonance as well 
as computed tomography (CT) imaging of the liver. The 
following clinical data were analyzed: age, sex, etiology of 
cirrhosis, Child–Pugh score (CPS), and model for end-stage 
liver disease (MELD) score. Moreover, the following labora-
tory values were collected: serum levels of hemoglobin, cre-
atinine, bilirubin, albumin, sodium, international normalized 
ratio (INR), aminotransferases, white and red blood cell and 
platelet counts as well as ammonium serum concentrations 
and alpha-fetoprotein (AFP) levels.
Patients were screened for the occurrence of complica-
tions until dismissal and at presentation at the following 
treatments. The LiMAx measurements were performed 
1 ± 1 day prior and 1 ± 1 day post-TACE treatment to study 
early changes after TACE. According to the pre-TACE 
LiMAx value, patients were divided into two groups: higher 
and lower than 150 µg/kg/h. This cutoff was based on a large 
study by Stockman et al. [7] where significantly worse out-
come for patients after hepatectomy with LiMAx under 
150 µg/kg/h was found. The ALBI score was calculated 
as follows and as previously described [6]: log10 bilirubin 
[mmol/L] × 0.66) + (albumin [g/L] × (− 0.0852)). ALBI 
classes were assessed as follows: ALBI score ≤ 2.60 (ALBI 
grade 1), ≥ 2.60 to ≤ 1.39 (ALBI grade 2), and ≥ 1.39 (ALBI 
grade 3) according to Johnson et al. [12].
TACE Procedure
TACE procedures were routinely prepared using analgetic 
and antiemetic oral medication including dexamethasone, 
ondansetron, and pethidine. Angiography was performed via 
a transfemoral route using an appropriate 4 French guiding 
catheter for catheterization of the celiac trunk or mesen-
teric artery to evaluate anatomical feasibility. A coaxial 2.7 
French microcatheter was used for selective angiography of 
the hepatic vasculature and to identify segmental hepatic 
tumor feeding arteries. For chemoembolization, a mixture 
of 10 ml  Lipiodol® Ultra Fluid (Guerbet, France) and 50 mg 
of doxorubicin was slowly injected to avoid non-target 
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embolization. A CT scan was conducted in all patients post-
TACE to allow for evaluation of embolized liver volume.
LiMAx Test
Liver tests were performed at the time of inclusion after 
fasting for a minimum of 3 h. The procedure is based on 
body weight-adjusted (2 mg/kg) intravenous 13C-labeled 
methacetin bolus injection and subsequent injection of 
20 ml 0.9% sodium chloride as previously described [13]. 
Exhaled breath is collected by a distinct two-way face mask 
and analyzed by means of a special device (Humedics, Ber-
lin, Germany). Herein, we are able to achieve a continuous 
real-time sampling rate and optimal analysis of delta-over-
baseline (DOB) curves of 13CO2/12CO2 ratios. 13C-methace-
tin is a substrate of the hepatic CYP1A2 enzyme, which 
exclusively metabolizes it into paracetamol and 13CO2 [14]. 
Prior to substrate injection, the baseline 13CO2/12CO2 ratio is 
recorded in the native expired air to calculate the individual 
baseline. Using the individual 13CO2/12CO2 baseline, the 
results are not influenced by obstructive pulmonary disease 
or ventilation. Maximum delta-over-baseline (DOBmax) 
of the 13CO2/12CO2 ratio was determined by analyzing the 
continuous DOB curve over a maximum of 60 min, and the 
LiMAx value is calculated as previously described [13]. The 
principle of the LiMAx test is illustrated in Fig. 1 (according 
to Stockmann et al. [13]).
Liver Volume Reduction and LiMAx Value Drop
Semi-automated liver volumetry was performed using a ded-
icated medical image viewing and postprocessing software 
(iNtuition, TeraRecon, NC, USA) pre- and post-TACE CT 
scans (available in all patients). The total liver volume (TLV) 
and tumor volume (TuV) were measured before TACE. The 
embolization volume (EV) was measured directly after 
TACE. LiMAx was performed 1 day (± 1) before and 1 day 
(± 1) after TACE treatment. A LiMAx drop was defined 
as: (LiMAx before TACE – LiMAx after TACE)/LiMAx 
before TACE *100 [%]. The Liver volume (LV) reduction 
was defined as: (TLV-TuV)-(TLV-EV)/(TLV-TuV) [%].
Assessment of Liver Function After TACE
LiMAx and liver function tests (thrombin time, bilirubin, 
transaminases) were measured at the first day after TACE 
treatment. Moreover, deterioration in clinical outcome, 
hospital stay, and post-interventional morbidity according 
to the Clavien–Dindo classification were recorded. A total 
bilirubin increase (total bilirubin after TACE – total biliru-
bin before TACE), albumin decrease (total albumin after 
Fig. 1  Principle of the LiMAx 
test. The test starts with a body 
weight-adjusted (2 mg/kg) intra-
venous 13C-labeled methacetin 
bolus injection and a subsequent 
injection of 20 ml 0.9% sodium 
chloride (1). 13C-methacetin 
is a substrate of the hepatic 
CYP1A2 enzyme, which is 
metabolized into paracetamol 
and 13CO2 (2), which is excreted 
pulmonary (3). Consecutively 
exhaled air is collected by a 
facemask (4) and then analyzed 
in a FLIP ® device according 
to the following formula (6). 
Adapted from Stockmann et al. 
[12]
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TACE – total albumin before TACE), and ALBI increase 
(total ALBI after TACE – total ALBI before TACE) were 
calculated as surrogate parameters for post-TACE treatment 
liver function deterioration.
Statistical Analysis
All variables are described as proportions, means with stand-
ard deviations (SD), or medians with interquartile ranges 
(IQR). Univariate analysis was performed with  Chi2-squared 
test, t test or Mann–Whitney U test, according to the dis-
tribution of the test variable. The statistical analyses were 
performed using SPSS 22.0 (SPSS, Munich, Germany). 
Two-sided p values < 0.05 were regarded as statistically 
significant. Coefficient of variations as well as Friedmann 
two-factorial rank analysis for repeated measures was used 
to compare repetitive LiMAx measurements before and after 
consecutive TACE in the same patient.
Results
Baseline Data
The patient baseline characteristics are summarized in 
Table 1. Twenty-one TACE procedures in 11 patients were 
included in the analysis. The patients were predominantly 
male (72%); the median age was 67 (± 11 SD) years. All of 
the patients had cirrhosis. The most common etiology was 
alcohol (64%), followed by hepatitis B (18%) and primary 
biliary cholangitis (18%)-induced cirrhosis. The patients 
were mostly in an early stage of cirrhosis (Child–Pugh 
stages: A 82%, B 18%, C 0%; median MELD score 9.9 
points ± 4 SD). Most patients were ALBI score grade 1 
(81.8%); 2 patients (18.2%) were grade 2. Median LiMAx in 
the ALBI grade 1 patients was 292 ± 168 µg/kg/h; in ALBI 
grade 2 patients LiMAx levels were lower (117 ± 37 µg/
kg/h), even though not reaching statistical significance 
(p = 0.12). No ALBI grade 3 patients were included.
HCC and TACE Treatments
Characteristics of the HCCs (Table 2) and TACE treatments 
(Table 3) are provided. The median size of the largest HCC 
nodule was 58.4 ± 24 mm. Most patients (87%) were BCLC 
stage B; 3 patients (13%) were in stage A3. The median 
TLV was 1755 ± 400 ml; median TuV of the HCCs was 
64.5 ± 6 ml. The median EV was 693 ± 400 ml. Most TACE 
was conducted in a selective lobar approach (70%).
Table 1  Baseline patients characteristics
Unless specified differently, values are given as median and standard 
deviation (SD), or frequencies and percentages
*p = 0.001 vs serum bilirubin before TACE. Significant p-values are 
indicated in bold
Age (years) 67 ± 11





ALBI score (mean) − 3.01 ± 0.4
Total bilirubin before TACE [mg/dl] 1.22 ± 0.8*
Total bilirubin after TACE [mg/dl] 1.91 ± 1.3*
Albumin [mg/dl] 36.4 ± 4
INR 1.16 ± 0.2
Creatinine [mg/dl) 1.05 ± 0.3
Platelets 102 ± 63
ALT [U/l] 39.6 ± 20
MELD 9.9 ± 4





Table 2  HCC characteristics
Values are given as median and standard deviation (SD), or frequen-
cies and percentages
Significant p-values are indicated in bold














AFP pre-TACE [µg/l] 842 ± 2106
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LiMAx and Function–Volume Analysis Pre‑ 
and Post‑TACE
The data are provided in Tables 2 and 3. The LiMAx lev-
els pre-TACE correlated with the pre-TACE ALBI score 
(p = 0.017, k = − 0.513) and albumin (p = 0.016, k = 0.519) 
levels, pre-TACE bilirubin (as item of the ALBI score) only 
(p = 0.065, k = − 0.41) were not significantly correlated 
with LiMAx levels pre-TACE though. Serum bilirubin 
levels were significantly higher after (1.91 ± 1.3 SD), than 
before (median 1.22 mg/dl ± 0.8 SD; p = 0.001) TACE. The 
median LiMAx levels before TACE were 276 ± 166 µg/kg/h; 
they were slightly reduced after TACE (251 ± 122 µg/kg/h; 
p = 0.08). This corresponded to a median drop of 7.1% of 
LiMAx levels after TACE. The LV was reduced median 
37.5 ± 23% SD. The reduction in LV did not correlate with 
the drop in LiMAx levels as presented in Fig. 2.
LV reduction (10.7–100%) and change of LiMAx lev-
els (− 37.8% to +40.0%) after TACE varied substantially 
among the patients and did not correlate significantly 
(p = 0.209, k = 0.302). When we compared patients with 
lower versus those with a higher (LiMAx ≤ 150 µg/kg/h 
versus > 150 µg/kg/h) LiMAx levels (Table 4), higher bili-
rubin and INR levels, larger spleen sizes, and lower plate-
let counts were observed in patients with lower LiMAx 
levels, which additionally in the setting of TACE confirms 
the well-known association of reduced LiMAx levels with 
the increasing stage of cirrhosis.
Notably, there was a significant correlation between 
LiMAx levels pre-TACE and the bilirubin increase after 
TACE (p = 0.019; Fig. 3). The increase in bilirubin was 
higher in the group of patients with LiMAx ≤ 150 µg/kg/h 
(Fig. 4c), whereas no difference could be detected for 
ALBI score and albumin levels (Fig. 4a and b).
Repetitive TACE
Most of the patients were treated multiple times (n = 18, 
78%): one patient was treated 5 times, one 4 times, one 3 
times, and 3 patients were treated twice. The longitudi-
nal data of LiMAx measurements in the patient with five 
treatments are presented in Fig. 5, there was no significant 
difference between LiMAx levels at different time points 
(p = 0.2), and this could also not be observed in the other 
patients. Overall, we noticed only few and minor compli-
cations post-TACE; 21 Patients (74%) had a normal post-
interventional course, in one patient (4%) Clavian–Dindo 
Grade I, and in five patients (22%) Clavian–Dindo Grade 
II (mostly acute cholecystitis) morbidity were observed.
Table 3  TACE and liver volume–function analysis parameters
Values are given as median and standard deviation (SD), or frequen-
cies and percentages
*p = 0.08 versus LiMAx before TACE. Significant p-values are indi-
cated in bold
TLV [ml] 1755 ± 400
TuV [ml] 64.5 ± 6






LiMAx before TACE [µg/kg/h] 276 ± 166
LiMAx after TACE [µg/kg/h] 251 ± 122*
LiMAx drop [%] 7.1 ± 23
LV reduction [%] 37.5 ± 23
Fig. 2  Poor correlation of FRLF 
und FLRV in patients after 
TACE
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Discussion
TACE is the gold standard therapy for patients with HCC 
in intermediate stages as endorsed by both the guidelines 
from the European Association for the Study of the Liver 
(EASL) [2] and the American Association for the Study 
of Liver Diseases (AASLD) [15, 16]. Two randomized 
controlled trials confirm the benefit of treatment for those 
patients in comparison with the best supportive care 
[17–19]. Post-TACE hepatic failure (PTHF) is one of the 
major complications after TACE. There are several risk 
factors for PTHF, including the presence of a portal vein 
thrombosis, reduced serum sodium and serum albumin 
levels, increased serum total bilirubin and AFP levels and 
reduced platelets count and large diameter of HCC [20]. 
Different scores including those parameters were devel-
oped. The ALBI score (albumin–bilirubin grade) [3–5, 21] 
and the BCLC criteria (based on the CPS [22]) are widely 
used prognostic markers for PTHF, but still are subopti-
mal. Therefore, other additional tests were developed in 
order to reduce the PTHF rate. Huang et al. [23] showed 
the superiority of the monoethylglycinexylidide test over 
conventional liver function tests and clinical parameters 
to predict PTHF. Similarly, Khisti et al. [24] showed a 
specificity of 87.5% and sensitivity of 90% for the liver 
function test with indocyanine green clearance to predict 
PTHF. There are also reports though, showing a non-supe-
riority of the indocyanine green plasma disappearance rate 
in order to predict PTHF compared to MELD, MELD-
Na, and CPS [25]. Still, there is no widely accepted gold 
standard for the evaluation of the liver function reserve in 
patients prior TACE treatment.
In this prospective pilot study, the feasibility of LiMAx 
measurements to assess the pre-TACE liver function was 
demonstrated. The LiMAx test has been intensively eval-
uated since its introduction in the year 2009 [13]. It was 
initially evaluated in hepatectomy patients. Using an algo-
rithm to predict posthepatectomy liver failure, including 
volume–function analysis [7], a significant improvement 
in the postoperative liver failure and mortality rate can be 
achieved as shown by Jara et al. [26]. Since there were some 
Table 4  Parameters stratified by 
LiMAx levels ≤/> 150 µg/kg/h. 
Values are given as median 
and standard deviation (SD), or 
frequencies and percentages






Total bilirubin before TACE [mg/dl] 1.4 ± 0.6 0.8 ± 0.6 0.01
Total bilirubin after TACE [mg/dl] 2.2 ± 0.8 1.1 ± 0.7 0.02
Total bilirubin rise [mg/dl] 0.81 ± 0.5 0.1 ± 0.2 0.01
Spleen size [cm] 18.0 ± 5 11.8 ± 3 0.004
Platelets count  [109/l] 70.0 ± 55 143.4 ± 42 0.01
ALT [U/l] 76.7 ± 150 42.3 ± 21 0.31
GGT [U/l] 148 ± 106 264 ± 245 0.55
AP [U/l] 179 ± 100 145 ± 73 0.19
INR 1.35 ± 0.1 1.01 ± 0.1 0.001
Fig. 3  Correlation of biliru-
bin increase after TACE and 
LiMAx levels before TACE
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considerations regarding an HCC functional status and the 
feasibility of volume–function analysis in those patients, 
Blüthner et al. [27] analyzed this algorithm in HCC patients 
with and without liver cirrhosis, yielding a similar result. 
As shown by Jara et al. [28], LiMAx can be repeatedly per-
formed even before and after extra-abdominal surgery lead-
ing to similar results.
A recent study by Barzakova et al. [29] also investigated 
LiMAx measurements in a similar approach to our cohort in 
patients undergoing TACE. Similar reductions to our cohort 
of LiMAx levels after TACE were found (10.0 versus 7.1%). 
As the cohort by Barzakova et al. contained > 65% of the 
patients with no cirrhosis, results can be not compared with 
our cohort.
In the present study, we found that LiMAx measure-
ments are reliable reproducible in patients with HCC and 
cirrhosis undergoing multiple TACE treatments. LiMAx 
levels did not correlate with ALBI levels, likely due to 
the similar stage of cirrhosis of the included patients. The 
functional liver volume reduction correlates very well 
with the drop of liver function measured by LiMAx in 
hepatectomy patients [13, 30]. LV changes were not cor-
related with changes of the LiMAx levels in our TACE 
patients though. We assume that this is due the fact that 
after TACE, there is no ’’real’’ liver parenchyma loss, 
since only portal, but no arterial branches are embolized. 
Fig. 4  a Post-TACE albumin change stratified by LiMAx levels. b Post-TACE ALBI change stratified by LiMAx levels. c Post-TACE bilirubin 
change stratified by LiMAx levels
Fig. 5  Course of LiMAx before and after TACE in the patient with 
five treatments. There was no significant difference between the sin-
gle measurements (p = 0.16). The coefficient of variations (CV) for 
the LiMAx before TACE was 15% and after TACE 5%. There was 
a drop of LiMAx value after the second TACE. This was associated 
with an episode of acute cholecystitis induced by TACE
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In addition, there is typically no necrosis within the embo-
lized liver after TACE. We thus assume that liver volume 
analysis prior TACE cannot stratify the risk of post-inter-
ventional liver failure, as it is the case in hepatectomy 
patients [7].
In contrast to ALBI and albumin levels, reduced LiMAx 
levels were associated with an increase in bilirubin after 
TACE. Even though this might also reflect changes in vas-
cularization after TACE or other confounders and, there-
fore, further studies are required, this may indicate that 
LiMAx could be an important marker to predict PTHF.
Our study has limitations that have to be acknowledged: 
our cohort size was small, and we had no case of major 
hepatic failure after TACE. This is due to a rigid selection 
of TACE candidates regarding preserved liver function. 
However, in this limited cohort of patients, results showed 
significant results indicating LiMAx as a robust method 
for assessment of liver function in cirrhotic liver. Occur-
rence of PTHF in the follow-up could therefore not be 
evaluated, and we therefore evaluated surrogate markers, 
but not clinical endpoints. Additionally, further studies 
investigating the optimal time point of LiMAx measure-
ments after TACE are required.
We conclude that in our prospective pilot trial, LiMAx 
measurements before TACE in order to predict PTHF are 
feasible and safe and show a strong intra-patient correla-
tion with reliable reproducible measurements in repetitive 
treatments. Lower LiMAx levels before TACE were asso-
ciated with surrogate markers indicating the liver function 
drop after TACE. Specific subgroups at high risk of PTHF 
should be investigated in dedicated future prospective tri-
als. This may facilitate the future development of strat-
egies to prevent the development of PTHF and identify 
patients at highest risk.
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